Literature DB >> 7803518

U-73122, a phospholipase C antagonist, inhibits effects of endothelin-1 and parathyroid hormone on signal transduction in UMR-106 osteoblastic cells.

A Tatrai1, S K Lee, P H Stern.   

Abstract

Endothelin-1 (ET-1) and parathyroid hormone (PTH) increase calcium transients in rodent osteoblastic cells. To investigate the role of phospholipase C (PLC) in these hormone-stimulated calcium signals, the effects of U-73122 (1-[6-[[17 beta-3-methoxyestra-1,3,5(10)- trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione), a reported PLC inhibitor, and its inactive analog, U-73343 (1-[6[[17 beta-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]- 1H-pyrrolidine-2,5-dione), were determined. Intracellular calcium transients were measured in UMR-106 cells with the fluorescent indicator fluo-3. In normal calcium containing medium, prior exposure (3 min) to U-73122 inhibited ET-1 and PTH stimulated calcium transients in a dose-dependent (0.2-10 microM) manner with an IC50 of 1.5-1.8 microM. A concentration of 6-8 microM was required for complete inhibition of responses to 100 nM ET-1 or PTH. U-73343 elicited no effects over this concentration range. In cells in which external calcium was reduced to less than 1 microM by the addition of EGTA, ET-1 signals were completely inhibited by 4-6 microM U-73122 and the IC50 was 0.8 microM. In the low external calcium medium, the PTH response was abolished by 2 microM U-73122 (IC50 = 0.5 microM). U-73122, 8 microM, significantly (P < 0.01) inhibited the effect of ET-1 on inositol trisphosphate production at 3 min whereas U-73343 did not. Pertussis toxin (100 ng/ml) likewise significantly inhibited the effect of ET-1 on phosphoinositol turnover as well as on intracellular calcium concentration. In conclusion, the results support the hypothesis that PLC plays a role in the calcium transients elicited by ET-1 and PTH, and that ET-1 transmits its signal in part via a pertussis toxin sensitive G-protein coupled receptor. Furthermore they suggest that U-73122 is useful for investigating PLC-mediated process in osteoblastic cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803518     DOI: 10.1016/0167-4889(94)90296-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Proliferating or differentiating stimuli act on different lipid-dependent signaling pathways in nuclei of human leukemia cells.

Authors:  Luca M Neri; Roberta Bortul; Paola Borgatti; Giovanna Tabellini; Giovanna Baldini; Silvano Capitani; Alberto M Martelli
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

2.  Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells.

Authors:  Luis Castro-Sanchez; Adriana Soto-Guzman; Margarita Guaderrama-Diaz; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

3.  Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium.

Authors:  H C Steel; R Anderson
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

4.  The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production.

Authors:  Ching-Hu Chung; Kuan-Ting Lin; Chien-Hsin Chang; Hui-Chin Peng; Tur-Fu Huang
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

5.  Involvement of calcium/calmodulin signaling in cercosporin toxin biosynthesis by Cercospora nicotianae.

Authors:  Kuang-Ren Chung
Journal:  Appl Environ Microbiol       Date:  2003-02       Impact factor: 4.792

6.  Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells.

Authors:  C A Power; D J Church; A Meyer; S Alouani; A E Proudfoot; I Clark-Lewis; S Sozzani; A Mantovani; T N Wells
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.